Jonathan Diamond, MD
Nephrology · Harrisburg, PANPI 1578539433
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $209,143 of the $248,986 with a category attached, or 84.0%. 31 manufacturers reported payments, led by Mallinckrodt Hospital Products Inc. at 42.4% of the total. Among nephrology clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 996 payments — averaging $249.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Mallinckrodt Hospital Products Inc.$105K
- Bayer$87K
- Mallinckrodt Enterprises LLC$33K
- Akebia Therapeutics Inc$9K
- AstraZeneca$3K
- Amgen$1K
- plus $10K from 25 others
What the payments were for
- Consulting fees$3,8282%
- Speaking & faculty fees$209,14384%
- Travel & lodging$16,3857%
- Food & beverage$18,7098%
- Education$8800%
- Gifts$410%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Mallinckrodt Hospital Products Inc. | 160 | $105,494 |
| Bayer | 90 | $87,220 |
| Mallinckrodt Enterprises LLC | 69 | $33,224 |
| Akebia Therapeutics Inc | 93 | $8,648 |
| AstraZeneca(2 entities) | 80 | $3,006 |
| Amgen(2 entities) | 44 | $1,311 |
| Vifor Pharma, Inc. | 52 | $1,105 |
| ANI Pharmaceuticals, Inc. | 84 | $1,083 |
| OPKO Pharmaceuticals, LLC | 45 | $1,030 |
| Otsuka America Pharmaceutical, Inc. | 39 | $993 |
| Travere Therapeutics, Inc. | 17 | $815 |
| Fresenius USA Marketing, Inc. | 29 | $735 |
| Ardelyx, Inc. | 54 | $718 |
| GSK | 20 | $607 |
| Calliditas Therapeutics US Inc. | 33 | $538 |
| Aurinia Pharma U.S., Inc. | 24 | $527 |
| Daiichi Sankyo Inc. | 15 | $449 |
| Novo Nordisk | 3 | $268 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 12 | $266 |
| Boehringer Ingelheim | 9 | $198 |
| Scpharmaceuticals Inc. | 4 | $182 |
| Novartis | 7 | $159 |
| E.r. Squibb & Sons, L.L.C. | 1 | $104 |
| Sanofi | 2 | $101 |
| Lilly USA, LLC | 3 | $53 |
| Alnylam Pharmaceuticals Inc. | 2 | $37 |
| Tersera Therapeutics LLC | 1 | $32 |
| Apellis Pharmaceuticals, Inc. | 1 | $26 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $24 |
| Ultragenyx Pharmaceutical Inc. | 1 | $21 |
| Baxter Healthcare | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$248,986 in reported general payments places this provider in the 95th percentile of 586 nephrology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 138 | $182,301 |
| LupkynisVoclosporin | 11 | $164,863 |
| JardianceEmpagliflozin | 67 | $73,857 |
| KerendiaFinerenone | 48 | $67,205 |
| AuryxiaFerric Citrate | 12 | $63,791 |
| VeltassaPatiromer Calcium Sorbitex | 38 | $32,271 |
| LokelmaSodium Zirconium Cyclosilicate | 20 | $16,771 |
| Cinacalcet Hcl | 55 | $11,433 |
| Sevelamer Carbonate | 24 | $9,417 |
| Calcitriol | 285 | $5,723 |
| Losartan Potassium | 197 | $3,447 |
| Nifedipine ErNifedipine | 49 | $1,852 |
| Spironolactone | 103 | $1,533 |
| Potassium Chloride | 15 | $1,250 |
| Hydralazine Hcl | 49 | $1,220 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Lokelma | $3,006 | $199,072158 claims |
| Aurinia Pharma U.S., Inc.Lupkynis | $527 | $164,86311 claims |
| Boehringer IngelheimJardiance | $198 | $73,85767 claims |
| BayerKerendia | $87,220 | $67,20548 claims |
| Akebia Therapeutics IncAuryxia | $8,648 | $63,79112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 586 nephrology providers in Pennsylvania.
Other nephrology in Harrisburg
- Nelson KopytAllentown$949K
- Christopher GislerPittsburgh$757K
- Rakesh GulatiPhiladelphia$657K
- Raymond TownsendPhiladelphia$357K
- Prince AnandDanville$331K
- Ellie KelepourisPhiladelphia$287K
- Abdallahsassine GearaPhiladelphia$225K
- Khaled NasharPittsburgh$198K
- Katalin SusztakPhiladelphia$192K
- Swati AroraPittsburgh$190K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.